Maia Biotechnology Revenue and Competitors

Chicago, IL USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Maia Biotechnology's estimated annual revenue is currently $4M per year.(i)
  • Maia Biotechnology's estimated revenue per employee is $155,000

Employee Data

  • Maia Biotechnology has 26 Employees.(i)
  • Maia Biotechnology grew their employee count by -24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.3M2856%N/AN/A
#2
$0.9M60%N/AN/A
#3
$2M130%N/AN/A
#4
$654.7M264029%$1.1BN/A
#5
$1.7M1157%N/AN/A
#6
$28.7M18525%N/AN/A
#7
$2.8M1864%N/AN/A
#8
$1.9M1233%N/AN/A
#9
$1.7M1157%N/AN/A
#10
$2M138%N/AN/A
Add Company

MAIA Biotechnology, Inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. MAIA's business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA's business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.

keywords:N/A

N/A

Total Funding

26

Number of Employees

$4M

Revenue (est)

-24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Maia Biotechnology News

2022-04-17 - MAIA Biotechnology, Inc. Announces FDA Orphan Drug ...

MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC).

2022-04-06 - Maia Biotechnology Looks To IPO For Cancer Treatment Development

Maia Biotechnology has filed to raise capital via a U.S. IPO. The firm is developing a novel approach to treating various cancers.

2022-03-22 - MAIA Biotechnology, Inc. Announces HREC Approval in ...

MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.8M26-24%$10M
#2
$1.8M268%$76.5M
#3
$2.5M26N/AN/A
#4
$2.6M26N/AN/A
#5
$2.6M26N/AN/A